One-Year Results of a Phase I/II Randomized, Double-Masked, Placebo-Controlled Study of Processed Amniotic Fluid Drops After PRK

被引:2
|
作者
Kirschenbaum, Malka Davina [1 ]
Hu, Katherine S. [1 ]
Ip, Colin S. [1 ]
Lin, Amy [1 ]
Pierce, Jan [2 ]
Holubkov, Richard [3 ]
Jensen, Hailey [3 ]
Mifflin, Mark D. [1 ]
机构
[1] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA
[2] Univ Utah, Cell Therapy & Regenerat Med, Salt Lake City, UT USA
[3] Univ Utah, Dept Pediat, Salt Lake City, UT USA
关键词
amniotic fluid; PRK; refractive; laser; MEMBRANE TRANSPLANTATION; SUSPENSION; OUTCOMES; EYE;
D O I
10.1097/ICO.0000000000003474
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose:The aim of this study was to evaluate the 1-year outcomes of using processed amniotic fluid (pAF) postoperatively after photorefractive keratectomy (PRK).Methods:Sixty-one participants were randomized to receive either placebo or pAF drops. The drops were instilled 4 times daily for 1 week after PRK along with routine postoperative medications. The primary outcome measures included uncorrected visual acuity, topographic corneal irregularity measurement, and surface staining over 1 year.Results:A statistically significant difference in uncorrected distance visual acuity between the placebo and treatment groups was seen at 1 month post-PRK, with a visual advantage evident in the pAF group. A suggestive difference in corneal irregularity measurement was also seen between the placebo and treatment groups at 1 month postsurgery, with less irregularity noted in the pAF group. No differences in uncorrected distance visual acuity or corneal irregularity measurement were found at 3, 6, and 12 months. There was also no significant difference in corneal staining scores between the 2 groups at any of the measured time points.Conclusions:This 1-year study evaluating the safety and efficacy of pAF as an additional postoperative topical medication after PRK demonstrated that pAF offered a mild visual advantage at 1 month post-PRK. There were no late adverse events, and the intervention proved safe at 1 year.
引用
收藏
页码:955 / 960
页数:6
相关论文
共 9 条
  • [1] Phase I/II randomized, double-masked, placebo-controlled study of processed amniotic fluid drops after PRK
    Ip, Colin S.
    Jones, D. Kyle
    Weinlander, Eric
    Gudgel, Brett
    Lin, Amy
    Yazdani, Hina
    Pierce, Jan
    Holubkov, Richard
    Jensen, Hailey
    Church, Myrna
    Mifflin, Mark D.
    JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2023, 49 (03): : 299 - 304
  • [2] The Use of Etoricoxib and Celecoxib for Pain Prevention After Periodontal Surgery: A Double-Masked, Parallel-Group, Placebo-Controlled, Randomized Clinical Trial
    Steffens, Joao Paulo
    Santos, Fabio Andre
    Pilatti, Gibson Luiz
    JOURNAL OF PERIODONTOLOGY, 2011, 82 (09) : 1238 - 1244
  • [3] Trimethoprim-Sulfamethoxazole Plus Azithromycin to Prevent Malaria and Sexually Transmitted Infections in Pregnant Women With HIV (PREMISE): A Randomized, Double-Masked, Placebo-Controlled, Phase IIB Clinical Trial
    Dionne, Jodie A.
    Anchang-Kimbi, Judith
    Hao, Jiaying
    Long, Dustin
    Apinjoh, Tobias
    Tih, Pius
    Mbah, Rahel
    Ngah, Edward Ndze
    Juliano, Jonathan J.
    Kahn, Mauricio
    Bruxvoort, Katia
    van der Pol, Barbara
    Tita, Alan T. N.
    Marrazzo, Jeanne
    Achidi, Eric
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (05):
  • [4] Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study
    Schneider, Simone
    Bailey, Mary
    Spears, Tracy
    Esther, Charles R., Jr.
    Laughon, Matthew M.
    Hornik, Christoph P.
    Jackson, Wesley
    BMC PEDIATRICS, 2020, 20 (01)
  • [5] Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure
    Sato, Naoki
    Takahashi, Wataru
    Hirayama, Atsushi
    Ajioka, Masayoshi
    Takahashi, Naoto
    Okishige, Kaoru
    Wang, XingLi
    Maki, Akio
    Maruyama, Hideki
    Ebinger, Ursula
    Yamaguchi, Masayuki
    Pang, Yinuo
    Matsumoto, Hiroki
    Kawana, Masatoshi
    CIRCULATION JOURNAL, 2015, 79 (06) : 1237 - +
  • [6] Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial
    Vahlquist, A.
    Blockhuys, S.
    Steijlen, P.
    van Rossem, K.
    Didona, B.
    Blanco, D.
    Traupe, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (01) : 173 - 181
  • [7] Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure - A Randomized, Double-Blind, Placebo-Controlled Phase II Study -
    Tsutsui, Hiroyuki
    Momomura, Shinichi
    Yamashina, Akira
    Ogawa, Hisao
    Shimokawa, Hiroaki
    Kihara, Yasuki
    Saito, Yoshihiko
    Hagiwara, Nobuhisa
    Ito, Hiroshi
    Ako, Junya
    Inomata, Takayuki
    Tanaka, Takashi
    Kawasaki, Yasushi
    CIRCULATION JOURNAL, 2016, 80 (03) : 668 - 676
  • [8] Traditional Chinese medicine, Danlou tablets alleviate adverse left ventricular remodeling after myocardial infarction: results of a double-blind, randomized, placebo-controlled, pilot study
    Mao, Shuai
    Wang, Lei
    Ouyang, Wenwei
    Zhou, Yuanshen
    Qi, Jianyong
    Guo, Liheng
    Zhang, Minzhou
    Hinek, Aleksander
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, 16
  • [9] Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial
    Tak, P. P.
    Mease, P. J.
    Genovese, M. C.
    Kremer, J.
    Haraoui, B.
    Tanaka, Y.
    Bingham, C. O., III
    Ashrafzadeh, A.
    Travers, H.
    Safa-Leathers, S.
    Kumar, S.
    Dummer, W.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (02): : 360 - 370